X-linked hypophosphatemia (XLH) is a disease where the body doesn’t retain enough phosphorus. Phosphorus is important for bone health, and when there is not enough phosphorus, bones can weaken over time.
CRYSVITA can help the body retain a normal amount of phosphorus.
CRYSVITA efficacy and safety have been studied in children and adults with XLH.
CRYSVITA is the first and only FDA-approved treatment for X-linked hypophosphatemia (XLH) that addresses the underlying cause of the disease.
Ask your doctor if CRYSVITA may be right for you.
UltraCare Patient Services for CRYSVITA is a program that provides information about how to access CRYSVITA.
Our services are designed to help you understand your insurance coverage and tell you if you are eligible for financial and patient assistance programs that can help make CRYSVITA affordable.
Please note a completed UltraCare Start Form is required for enrollment.
Visit UltraCare for CRYSVITA
XLH patients, Sara and Aly
XLH is a chronic bone disease that affects the lives of children and adults who have it.
